Similar articles

• The treatment of viral hepatitis, present and future.

  Rodés J. Rodés J. J Hepatobiliary Pancreat Surg. 2003;10(2):163-7. doi: 10.1007/s00534-002-0722-x. J Hepatobiliary Pancreat Surg. 2003. PMID: 14505150 No abstract available.
• PEG-IFN, RBV dosing during chronic HCV re-treatment.

  Highleyman L. Highleyman L. IAPAC Mon. 2007 Feb;13(2):55. IAPAC Mon. 2007. PMID: 17948601 No abstract available.
• [High dose repeat therapy in previously treated patients with chronic hepatitis C].

  Hoepffner N, Paul KA, Nikodem AB, Teuber G. Hoepffner N, et al. Dtsch Med Wochenschr. 2006 Mar 17;131(11):543-4. doi: 10.1055/s-2006-933693. Dtsch Med Wochenschr. 2006. PMID: 16538557 Review. German. No abstract available.
• [Advance in the management of the difficult-to-treat patients with chronic hepatitis C].

  Xie Y, Li MH. Xie Y, et al. Zhonghua Gan Zang Bing Za Zhi. 2009 Jul;17(7):484-6. Zhonghua Gan Zang Bing Za Zhi. 2009. PMID: 19912677 Chinese. No abstract available.
• [Interferons alpha in the treatment of chronic HCV infections].

  Halota W, Pawłowska M, Andrejczyn M. Halota W, et al. Przegl Epidemiol. 2004;58(3):405-11. Przegl Epidemiol. 2004. PMID: 15730004 Review. Polish.